Literature DB >> 10629010

Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates.

J A Hoogkamp-Korstanje1, J Roelofs-Willemse.   

Abstract

The in vitro activity of moxifloxacin was compared with that of 15 antibacterial agents against 513 Gram-positive microorganisms. The MIC(90) (mg/L) of moxifloxacin was 0.06 for quinolone-susceptible Staphylococcus aureus and Staphylococcus epidermidis, 0.12 for Streptococcus pyogenes and Streptococcus agalactiae; 0.25 for Streptococcus pneumoniae, Streptococcus mitis, Streptococcus bovis, Streptococcus anginosus and Actinomyces pyogenes; 0.5 for Streptococcus sanguis and Listeria monocytogenes, 2 for Corynebacterium jekeium and Bifidobacterium bivius. Over 50% of Enterococcus faecalis, Enterococcus faecium, quinolone-resistant staphylococci, Nocardia steroides and Clostridium difficile were susceptible to 2 mg/L moxifloxacin. Moxifloxacin and trovafloxacin demonstrated comparably high activity towards Gram-positive cocci; moxifloxacin and clinafloxacin were most active against Gram-positive bacilli.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10629010     DOI: 10.1093/jac/45.1.31

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

1.  National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents.

Authors:  L D Liebowitz; M Slabbert; A Huisamen
Journal:  J Clin Pathol       Date:  2003-05       Impact factor: 3.411

2.  Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare-associated pneumonia.

Authors:  Karl J Madaras-Kelly; Richard E Remington; Vincent S Fan; Kevin L Sloan
Journal:  J Hosp Med       Date:  2011-10-28       Impact factor: 2.960

Review 3.  Alternative strategies for proof-of-principle studies of antibacterial agents.

Authors:  Axel Dalhoff; Andrej Weintraub; Carl Erik Nord
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

Review 4.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Aggregatibacter actinomycetemcomitans biofilm killing by a targeted ciprofloxacin prodrug.

Authors:  Benjamin D Reeves; Mark Young; Paul A Grieco; Peter Suci
Journal:  Biofouling       Date:  2013-08-19       Impact factor: 3.209

6.  gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.

Authors:  Larbi Dridi; Jacques Tankovic; Béatrice Burghoffer; Frédéric Barbut; Jean-Claude Petit
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

7.  Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors.

Authors:  Stéphane Bronner; François Jehl; Jean-Daniel Peter; Marie-Cécile Ploy; Corinne Renault; Pierre Arvis; Henri Monteil; Gilles Prevost
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

8.  Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.

Authors:  G Ackermann; Y J Tang; R Kueper; P Heisig; A C Rodloff; J Silva; S H Cohen
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

9.  Fluoroquinolones in the Treatment of Meningitis.

Authors:  Philippe Cottagnoud; Martin G. Täuber
Journal:  Curr Infect Dis Rep       Date:  2003-08       Impact factor: 3.725

Review 10.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.